Asymmetries and visual field summaries as predictors of glaucoma in the ocular hypertension treatment study.

Anthropometric measures and their relation to incident primary open-angle glaucoma. Ophthalmology (2010) 2.15

The rate of visual field change in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci (2012) 0.98

Symmetry between the right and left eyes of the normal retinal nerve fiber layer measured with optical coherence tomography (an AOS thesis). Trans Am Ophthalmol Soc (2008) 0.92

Predicting progressive glaucomatous optic neuropathy using baseline standard automated perimetry data. Invest Ophthalmol Vis Sci (2008) 0.89

The accuracy and clinical application of predictive models for primary open-angle glaucoma in ocular hypertensive individuals. Ophthalmology (2008) 0.85

Frequency Doubling Technology vs Standard Automated Perimetry in Ocular Hypertensive Patients. Open Ophthalmol J (2009) 0.77

Baseline factors predicting the risk of conversion from ocular hypertension to primary open-angle glaucoma during a 10-year follow-up. Eye (Lond) (2016) 0.75

Efficacy and tolerability of a large scale change in regimen from latanoprost to travoprost in glaucoma patients at the Manhattan Veterans Administration Hospital. Clin Ophthalmol (2008) 0.75

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89

The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 11.38

Classification of visual field abnormalities in the ocular hypertension treatment study. Arch Ophthalmol (2003) 1.76

Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group. Arch Ophthalmol (2000) 1.62

Structure and function evaluation (SAFE): II. Comparison of optic disk and visual field characteristics. Am J Ophthalmol (2003) 1.53

Correlation of asymmetric damage with asymmetric intraocular pressure in normal-tension glaucoma (low-tension glaucoma). Arch Ophthalmol (1988) 1.50

Structure and function evaluation (SAFE): I. criteria for glaucomatous visual field loss using standard automated perimetry (SAP) and short wavelength automated perimetry (SWAP). Am J Ophthalmol (2002) 1.49

Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology (2002) 1.46

Unequal intraocular pressure and its relation to asymmetric visual field defects in low-tension glaucoma. Ophthalmology (1989) 1.32

Static threshold asymmetry in early glaucomatous visual field loss. Ophthalmology (1989) 0.86

Informational content of visual field location in glaucoma. Doc Ophthalmol (1985) 0.84

Automated perimetry and short wavelength sensitivity in patients with asymmetric intraocular pressures. Graefes Arch Clin Exp Ophthalmol (1993) 0.82

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89

The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 11.38

A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol (2003) 9.99

High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol (2003) 3.13

Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol (2010) 2.78

In vivo imaging of the photoreceptor mosaic in retinal dystrophies and correlations with visual function. Invest Ophthalmol Vis Sci (2006) 2.78

Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol (2004) 2.39

Reduction in intraocular pressure after cataract extraction: the Ocular Hypertension Treatment Study. Ophthalmology (2012) 2.35

Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology (2006) 2.28

Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol (2010) 2.14

The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol (2004) 2.03

Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol (2004) 2.01

Perimetry, retinal nerve fiber layer thickness and papilledema grade after cerebrospinal fluid shunting in patients with idiopathic intracranial hypertension. J Neuroophthalmol (2015) 1.99

Baseline topographic optic disc measurements are associated with the development of primary open-angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol (2005) 1.80

Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol (2004) 1.80

Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol (2006) 1.80

Classification of visual field abnormalities in the ocular hypertension treatment study. Arch Ophthalmol (2003) 1.76

Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol (2004) 1.71

Evaluation of the structure-function relationship in glaucoma. Invest Ophthalmol Vis Sci (2005) 1.64

The utility of the monocular trial: data from the ocular hypertension treatment study. Ophthalmology (2010) 1.61

Quantitation of cardiolipin molecular species in spontaneously hypertensive heart failure rats using electrospray ionization mass spectrometry. J Lipid Res (2005) 1.61

Pulsar perimetry in the diagnosis of early glaucoma. Am J Ophthalmol (2009) 1.57

The Nature of Macular Damage in Glaucoma as Revealed by Averaging Optical Coherence Tomography Data. Transl Vis Sci Technol (2012) 1.55

Normative ranges and specificity of the multifocal VEP. Doc Ophthalmol (2004) 1.52

Neurologic impairment 10 years after optic neuritis. Arch Neurol (2004) 1.51

Changes in cellular structures revealed by ultra-high resolution retinal imaging in optic neuropathies. Invest Ophthalmol Vis Sci (2008) 1.51

Racial differences in optic disc topography: baseline results from the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study. Arch Ophthalmol (2004) 1.49

Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology (2002) 1.46

Comparison of different methods for detecting glaucomatous visual field progression. Invest Ophthalmol Vis Sci (2003) 1.46

Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. Ophthalmology (2006) 1.44

Is a history of diabetes mellitus protective against developing primary open-angle glaucoma? Arch Ophthalmol (2008) 1.43

The idiopathic intracranial hypertension treatment trial: design considerations and methods. J Neuroophthalmol (2014) 1.40

Frequency-doubling technology perimetry. Ophthalmol Clin North Am (2003) 1.34

Identification of progressive glaucomatous visual field loss. Surv Ophthalmol (2002) 1.33

Interaction trees with censored survival data. Int J Biostat (2008) 1.31

Properties of perimetric threshold estimates from full threshold, ZEST, and SITA-like strategies, as determined by computer simulation. Invest Ophthalmol Vis Sci (2003) 1.30

How useful is population data for informing visual field progression rate estimation? Invest Ophthalmol Vis Sci (2013) 1.29

Psychophysical investigation of ganglion cell loss in early glaucoma. J Glaucoma (2005) 1.29

The Ocular Hypertension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center. Am J Ophthalmol (2002) 1.27

Development of efficient threshold strategies for frequency doubling technology perimetry using computer simulation. Invest Ophthalmol Vis Sci (2002) 1.27

Selective loss of an oscillatory component from temporal retinal multifocal ERG responses in glaucoma. Invest Ophthalmol Vis Sci (2002) 1.26

Comparing multifocal VEP and standard automated perimetry in high-risk ocular hypertension and early glaucoma. Invest Ophthalmol Vis Sci (2007) 1.24

Determining abnormal latencies of multifocal visual evoked potentials: a monocular analysis. Doc Ophthalmol (2004) 1.23

Adjusting intraocular pressure for central corneal thickness does not improve prediction models for primary open-angle glaucoma. Ophthalmology (2011) 1.23

Using machine learning classifiers to identify glaucomatous change earlier in standard visual fields. Invest Ophthalmol Vis Sci (2002) 1.23

Staging functional damage in glaucoma: review of different classification methods. Surv Ophthalmol (2007) 1.20

Test-retest reproducibility of optic disk deterioration detected from stereophotographs by masked graders. Am J Ophthalmol (2005) 1.20

Characteristics of the normative database for the Humphrey matrix perimeter. Invest Ophthalmol Vis Sci (2005) 1.19

Flavin-dependent antioxidant properties of a new series of meso-N,N'-dialkyl-imidazolium substituted manganese(III) porphyrins. Biochem Pharmacol (2004) 1.19

Community visual field screening: prevalence of follow-up and factors associated with follow-up of participants with abnormal frequency doubling perimetry technology results. Ophthalmic Epidemiol (2007) 1.18

Longitudinal and cross-sectional analyses of visual field progression in participants of the Ocular Hypertension Treatment Study. Arch Ophthalmol (2010) 1.18

Multifocal electroretinogram: age-related changes for different luminance levels. Graefes Arch Clin Exp Ophthalmol (2002) 1.17

The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study. Ophthalmology (2006) 1.16

Comparison of the new perimetric GATE strategy with conventional full-threshold and SITA standard strategies. Invest Ophthalmol Vis Sci (2008) 1.16

Performance of efficient test procedures for frequency-doubling technology perimetry in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci (2002) 1.14

Effect of dichoptic adaptation on frequency-doubling perimetry. Optom Vis Sci (2002) 1.14

Evidence of outer retinal changes in glaucoma patients as revealed by ultrahigh-resolution in vivo retinal imaging. Br J Ophthalmol (2010) 1.13

Comparison of glaucomatous visual field defects using standard full threshold and Swedish interactive threshold algorithms. Arch Ophthalmol (2002) 1.12

Frequency-doubling technology perimetry and optical defocus. Invest Ophthalmol Vis Sci (2003) 1.11

Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol (2002) 1.10

The Heidelberg retina tomograph Glaucoma Probability Score: reproducibility and measurement of progression. Ophthalmology (2010) 1.10

The methodology of visual field testing with frequency doubling technology in the National Health and Nutrition Examination Survey, 2005-2006. Ophthalmic Epidemiol (2010) 1.09

Size threshold perimetry performs as well as conventional automated perimetry with stimulus sizes III, V, and VI for glaucomatous loss. Invest Ophthalmol Vis Sci (2013) 1.09

Fourier-domain optical coherence tomography and adaptive optics reveal nerve fiber layer loss and photoreceptor changes in a patient with optic nerve drusen. J Neuroophthalmol (2008) 1.09

Visualization of lipofuscin accumulation in Stargardt macular dystrophy by high-resolution Fourier-domain optical coherence tomography. Arch Ophthalmol (2007) 1.09

Anterior lamina cribrosa surface depth, age, and visual field sensitivity in the Portland Progression Project. Invest Ophthalmol Vis Sci (2014) 1.08

The repeatability of mean defect with size III and size V standard automated perimetry. Invest Ophthalmol Vis Sci (2013) 1.06

Variability of intraocular pressure measurements in observation participants in the ocular hypertension treatment study. Ophthalmology (2009) 1.06

The confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study: study design and baseline factors. Am J Ophthalmol (2004) 1.06

Predicting the onset of glaucoma: the confocal scanning laser ophthalmoscopy ancillary study to theOcular Hypertension Treatment Study. Ophthalmology (2010) 1.05

Determining abnormal interocular latencies of multifocal visual evoked potentials. Doc Ophthalmol (2004) 1.05

Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. Am J Ophthalmol (2006) 1.05

Glaucomatous progression in series of stereoscopic photographs and Heidelberg retina tomograph images. Arch Ophthalmol (2010) 1.04

Comparing the effectiveness of telemedicine and traditional surveillance in providing diabetic retinopathy screening examinations: a randomized controlled trial. Telemed J E Health (2013) 1.04

Factors predicting the rate of functional progression in early and suspected glaucoma. Invest Ophthalmol Vis Sci (2012) 1.04